Patients treated with antibiotics previously, but not concurrently, to anti-PD-1 or anti-PD-L1 immunotherapy have been shown to have worse overall survival across multiple types of cancer, including NSCLC and melanoma,131 further showing that the gut microbiota is implicated in both of these immunotherapies. Here, CD274 is linked to melanoma.